Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia by Schnell, Gretja et al.
Compartmentalized Human Immunodeficiency Virus
Type 1 Originates from Long-Lived Cells in Some
Subjects with HIV-1–Associated Dementia
Gretja Schnell
1, Serena Spudich
2, Patrick Harrington
3,4¤, Richard W. Price
2, Ronald Swanstrom
1,3,4*
1Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, United States of America,
2Department of Neurology, University of California at San Francisco, San Francisco General Hospital, San Francisco, California, United States of America, 3Lineberger
Comprehensive Cancer Center, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, United States of America, 4UNC Center for AIDS
Research, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, United States of America
Abstract
Human immunodeficiency virus type 1 (HIV-1) invades the central nervous system (CNS) shortly after systemic infection and
can result in the subsequent development of HIV-1–associated dementia (HAD) in a subset of infected individuals.
Genetically compartmentalized virus in the CNS is associated with HAD, suggesting autonomous viral replication as a factor
in the disease process. We examined the source of compartmentalized HIV-1 in the CNS of subjects with HIV-1–associated
neurological disease and in asymptomatic subjects who were initiating antiretroviral therapy. The heteroduplex tracking
assay (HTA), targeting the variable regions of env, was used to determine which HIV-1 genetic variants in the cerebrospinal
fluid (CSF) were compartmentalized and which variants were shared with the blood plasma. We then measured the viral
decay kinetics of individual variants after the initiation of antiretroviral therapy. Compartmentalized HIV-1 variants in the
CSF of asymptomatic subjects decayed rapidly after the initiation of antiretroviral therapy, with a mean half-life of 1.57 days.
Rapid viral decay was also measured for CSF-compartmentalized variants in four HAD subjects (t1/2 mean=2.27 days).
However, slow viral decay was measured for CSF-compartmentalized variants from an additional four subjects with
neurological disease (t1/2 range=9.85 days to no initial decay). The slow decay detected for CSF-compartmentalized variants
was not associated with poor CNS drug penetration, drug resistant virus in the CSF, or the presence of X4 virus genotypes.
We found that the slow decay measured for CSF-compartmentalized variants in subjects with neurological disease was
correlated with low peripheral CD4 cell count and reduced CSF pleocytosis. We propose a model in which infiltrating
macrophages replace CD4
+ T cells as the primary source of productive viral replication in the CNS to maintain high viral
loads in the CSF in a substantial subset of subjects with HAD.
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Introduction
Human immunodeficiency virus type 1 (HIV-1)-associated
dementia (HAD) is a severe neurological disease that affects a
subset of HIV-1-infected individuals [1,2]. HIV-1 infection of the
central nervous system (CNS) occurs shortly after peripheral
infection, most likely through the trafficking of infected lympho-
cytes and monocytes across the blood-brain barrier (BBB) [3,4].
Once HIV-1 crosses the BBB it can infect perivascular
macrophages and brain-resident microglia, and some studies have
shown that neurotropic viruses preferentially infect macrophages
[5–8]. HIV-1 may persist in the CNS during therapy due to the
insufficient CNS penetration of some antiretroviral drugs [2,9–11].
HIV-1 variants have been detected at autopsy in the brains of
HAD subjects, and these brain-derived variants are genetically
distinct from virus detected in the peripheral blood [7,12–15]. A
principal impediment to studying viral evolution in the CNS is that
direct sampling of HIV-1 in brain tissue is usually possible only
once, at biopsy or autopsy. To examine viral populations in the
CNS over the course of HIV-1 infection we have relied upon
repeated sampling of virus in the cerebrospinal fluid (CSF).
Previous studies have shown that virus detected in the CSF
originates from both local CNS tissue and the peripheral blood
[16–19], indicating that the CSF may act as a site of mixing of
virus present in the brain and the periphery. In addition, genetic
compartmentalization has been reported between blood plasma
and CSF viral variants [20–23]. We previously examined the
cellular sources of HIV-1 in the CNS by utilizing the heteroduplex
tracking assay (HTA) to measure viral decay rates in HIV-1-
infected subjects initiating antiretroviral therapy [24]. In this study
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the CSF of four asymptomatic subjects decayed rapidly after the
initiation of therapy, suggesting that the compartmentalized virus
is coming from a short-lived cell type, such as CD4
+ T cells [24].
The population dynamics of systemic HIV-1 replication have
been studied extensively [25–27], but the extent of viral replication
in specific cell types in the CNS over the course of disease is not yet
known. The use of antiretroviral drugs to prevent HIV-1 infection
of uninfected cells provides a tool for ‘‘viewing’’ the rate of decay
for cell-free virus and virally-infected cells. HIV-1 decay in
peripheral blood after the initiation of highly active antiretroviral
therapy (HAART) occurs in at least two phases [25,27]. The first
phase of decay is rapid and has been proposed to represent the
turnover of cell-free virions and productively infected CD4
+ T cells
[25–28]. The second phase is slower and may reflect the decay of
long-lived infected cells, possibly latently infected resting CD4
+ T
cells and cells of the monocyte lineage [25,27–29], and the release
of virions from follicular dendritic cells [28,30]. Recently, a study
using the integrase inhibitor raltegravir reported altered HIV-1
decay kinetics and a reduction of the second viral decay phase
[31], suggesting integration as a rate limiting step of infection in a
subset of cells. The implications of these data on measured viral
decay rates remain to be clarified; however, the reduction in the
second phase of HIV-1 decay may indicate that longer-lived HIV-
1-infected cells contribute less to total viral load than previously
thought, but it does not preclude the possibility that the second
phase of HIV-1 decay may reflect the turnover of long-lived cells
[31,32].
In this study, we characterized the lifespan of the cellular source
of compartmentalized HIV-1 in the CNS of subjects with and
without symptomatic neurological disease by calculating viral
decay rates during the initiation of antiretroviral therapy. The
heteroduplex tracking assay (HTA) [33,34] was used to distinguish
between HIV-1 genetic variants in the CSF that were either
compartmentalized to the CSF or equilibrated with the peripheral
blood. HTA has been used in previous studies to differentiate
between HIV-1 genetic variants in separate anatomical compart-
ments [22,24,35,36] and HIV-1 evolutionary variants [37–42],
including drug resistance mutations [43,44]. The HTA is a useful
tool for resolving and quantifying complex viral populations based
on their genotype, and is able to detect HIV-1 variants that
comprise as little as 1–3% of the total viral population. We
targeted the variable regions of the env gene for HTA analysis of
our subject population in order to resolve multiple HIV-1 genetic
variants. In this study we confirm rapid viral decay in the CSF of
asymptomatic subjects initiating HAART, and we report reduced
rates of viral decay of compartmentalized virus in the CSF in a
subset of neurologically symptomatic subjects initiating antiretro-
viral therapy. These results suggest a shift in the cell type that
produces the bulk of the virus in the CSF late in disease as part of
the process of viral pathogenesis in the CNS.
Results
Subject population characteristics
Our analysis included 11 asymptomatic subjects (7 new subjects,
4 subjects reported in [24]), 1 subject with minor cognitive motor
disorder (MCMD), and 7 subjects with HIV-1–associated
dementia (HAD; see Table 1). In general, subjects with HAD
have higher viral load in the CSF [17,45,46] and increased HIV-1
compartmentalization in the CSF [21,22]. To assess compart-
mentalization we measured the relative abundance of HIV-1
variants in the blood plasma and CSF as resolved by the
heteroduplex tracking assay (HTA), then calculated the percent
difference values between the two viral populations (see Table 2).
We found that the CSF and plasma viral populations were
different for subjects with HIV-associated neurological disease
(average=67% different; range=36–88% different) compared to
the asymptomatic subjects (average=42% different; range=10–
78% different). This difference approached statistical significance
in spite of the small sample size (p=0.054 using a two-tailed
Mann-Whitney test), and this trend of increased viral compart-
mentalization in the CSF with HAD is consistent with the
difference seen in a larger cross-sectional analysis [21]. We next
used the HTA to follow differential decay of shared and
compartmentalized variants when subjects initiated therapy. In
this study, the subjects had an average reduction of 91% of the
virus in the blood, and 88% of the virus in the CSF, over the
period of sampling for HTA analysis (Table 2).
Compartmentalized HIV-1 in the CSF of asymptomatic
subjects decays rapidly
The HTA is a useful tool for sampling complex viral
populations, and is sensitive enough to detect minor variants
within the population. We utilized HTAs targeting the hyper-
variable regions V1/V2 and V4/V5 of the env gene to detect and
measure the decay of individual HIV-1 variants in the cerebro-
spinal fluid and plasma of subjects initiating HAART. The HTA
that was the most reproducible (V1/V2 or V4/V5) was used for
the final decay and half-life calculations. The half-lives for the
different variants in the blood for four of these subjects have been
reported previously [47].
The V1/V2 and V4/V5 HTA analyses for the seven new
asymptomatic subjects revealed rapid HIV-1 decay for both
compartmentalized and shared variants detected in the CSF (see
Figure 1). The decay of individual variants was organized into two
groups for half-life analysis: decay of CSF-compartmentalized
variants and decay of variants shared between the blood and the
CSF. The HTA gels for the longitudinal samples from the seven
new asymptomatic subjects are shown in Figure 1A, and graphs
representing the viral decay are shown in Figure 1B. In this
Author Summary
Infection of the central nervous system (CNS) with human
immunodeficiency virus type 1 (HIV-1) can lead to the
development of HIV-1–associated dementia, a severe
neurological disease that results in cognitive and motor
impairment. Individuals that are chronically infected with
HIV-1 sometimes display unique viral variants in their
cerebrospinal fluid (CSF) that are not detected in the blood
virus population, termed CSF-compartmentalized variants.
The cell type that produces CSF-compartmentalized virus
throughout the course of infection has not been
determined. We used a sensitive assay to detect compart-
mentalized variants in the CSF of subjects with and
without neurological disease, and then measured the
decay kinetics of compartmentalized virus when subjects
were starting antiretroviral therapy. We found that
compartmentalized virus decays rapidly in asymptomatic
subjects. Additionally, we detected differential decay (i.e.
rapid or slow) in subjects with neurological disease, and
this was associated with the number of white blood cells in
the CSF. Our data supports a model of HIV-1 infection in
the CNS where compartmentalized virus is produced by a
long-lived cell type (slow decay), and this virus can be
amplified by short-lived cells (rapid decay) that traffic into
the CNS, but is increasingly produced from long-lived cells
in the immunodeficient state.
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increasing percentage of the total viral population over the course
of therapy. However, if all variants decay at the same rate then the
relative percentages will remain the same over time. HIV-1 half-
lives for plasma and CSF variants were calculated based on the
slopes of the decay curves (summarized in Table 2). Based on data
generated from the seven new asymptomatic subjects analyzed in
this study, half-lives calculated for the total plasma viral load decay
were short (t1/2 mean=1.46 days; t1/2 range=0.58–2.27 days),
and total CSF viral load half-lives were short (t1/2 mean=1.5 days;
t1/2 range=0.77–2.04 days). These half-lives are similar to the
data reported for 4 asymptomatic subjects that were previously
studied [24].
Although some asymptomatic subjects have large percent
difference values between the blood and CSF viral populations,
not all of the variants detected in the CSF met the criteria for
compartmentalization. Viral variants in the CSF were considered
compartmentalized if they were unique to the CSF or they were
present in a substantially higher concentration in the CSF
compared to the plasma. CSF-compartmentalized variants were
detected in asymptomatic subjects 5005, 4014, and 4022. To
increase our sample size we included the half-life data from the
four asymptomatic subjects reported in ref. [24] in our analysis of
CSF-compartmentalized decay. Including these additional four
subjects (n=7 total asymptomatic subjects with some compart-
mentalized virus: 3 new subjects and 4 previously reported
subjects), we found that the half-lives for CSF-compartmentalized
variants in these subjects were short, with a mean of 1.57 days (t1/2
range=0.75–2.75 days; see below). These data indicate that CSF-
compartmentalized virus in asymptomatic subjects is most likely
originating from a short-lived cell type, such as a CD4
+ T cell. The
reported half-life of a productively infected CD4
+ T cell is
approximately 2 days [28], which coincides with our average
measured half-life of 1.57 days in these subjects.
Differential decay of compartmentalized HIV-1 in the CSF
of neurologically symptomatic subjects is correlated with
immunodeficiency and CSF pleocytosis
We expanded our analysis of viral decay to HIV-1-infected
subjects who were diagnosed with either MCMD or HAD to
address the hypothesis that CSF-compartmentalized variants in
these subjects originate from longer-lived cells. Viral decay in the
CSF of eight subjects with neurological disease was analyzed using
HTAs targeting the V1/V2 and V4/V5 regions of env. The HTA
analyses for the eight subjects with HIV-associated neurological
disease showed either rapid or slow viral decay among the subjects.
The longitudinal HTA gels for each neurologically symptomatic
subject are shown in Figure 2A, and the graphs of viral decay are
shown in Figure 2B and 2C. Similar to the asymptomatic subject
decay analysis, individual variants were grouped as either CSF-
compartmentalized variants or variants shared between the blood
and the CSF for the decay analysis.
Total plasma viral load decay was rapid for all subjects with
neurological disease, with a mean half-life of 2.11 days (t1/2
range=1.42–2.91 days; summarized in Table 2 and Figure 3). We
measured rapid viral decay for CSF-compartmentalized variants
after the initiation of HAART for four subjects with HAD (4033,
5003, 7036, 4051; t1/2 mean=2.27 days; t1/2 range=1.23–3.67
days; Figure 2B and Figure 3; summarized in Table 2), similar to
asymptomatic subjects. In contrast, prolonged viral decay was
measured for CSF-compartmentalized variants for the other four
subjects with neurological disease (4013, 5002, 4059, 7115; t1/2
range=9.85 days to no initial decay), with three subjects
displaying biphasic decay. CSF-compartmentalized variants for
subjects 4013, 5002, and 7115 displayed a biphasic decay (see
Figure 2C), where the first phase of viral decay was slow (4013 t1/
2=28.5 days; 7115 t1/2=no initial decay; 5002 t1/2=no initial
decay), and the second phase was faster (4013 t1/2=3.9 days; 7115
t1/2=6.4 days; 5002 t1/2=4.24 days). Figure 3 and Table 2 report
Table 1. Sample characteristics.
Subject ID Cell counts (cells/ml) ADC Stagec Drug Regimen CPE totald HIV-1 RNA (log10 copies/ml)
a
CD4
a CSF WBC
b Plasma CSF
4012 295 13 0 3TC, NVP, NFV, AZT 2.5 5.18 4.39
4014 1140 20 0 ddI, NVP, d4T 1.5 4.41 4.42
4021 215 2 0 AZT, 3TC, NFV 1.5 4.97 4.02
4022 372 18 0 3TC, NFV, AZT 1.5 4.58 4.77
4023 215 0 0 AZT, 3TC, NFV, EFV 2.0 5.50 3.77
4030 239 5 0 d4T, 3TC, EFV 1.5 4.86 4.06
5005 267 19 0 ABC, NVP, SGC, NFV 2.0 5.30 4.99
4033 173 28 2 IDV, RTV, 3TC, ABC, NVP 3.5 4.83 5.23
4051 344 26 3 AZT, 3TC, EFV 2.0 5.61 5.41
5003 234 39 3 NFV, d4T, ABC 1.5 3.31 4.33
7036 267 150 2 AZT, 3TC, NVP 2.5 5.12 5.37
4013 148 6 1 3TC, NVP, NFV, d4T 2.0 4.62 4.75
4059 53 1 3 AZT, 3TC, LPVr 2.5 5.31 5.08
5002 59 23 3 3TC, NVP, NFV, ABC 2.5 4.24 5.32
7115 50 9 2 AZT, 3TC, LPVr 2.5 5.87 4.85
aBaseline samples.
bAverage CSF white blood cell counts over the first 14 days of antiretroviral therapy.
cADC staging: [68].
dCNS Penetration Effectiveness Rank total. The CPE ranks for each drug in the regimen were summed to get the CPE total.
doi:10.1371/journal.ppat.1000395.t001
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displayed only a slower decay rate for the CSF-compartmentalized
variants (t1/2=9.85 days). Total CSF viral load decay was similar
to the decay rates measured for CSF-compartmentalized variants
for all subjects with neurological disease. This is due to the fact
that most of the virus in the CSF was compartmentalized in these
HAD subjects. The decay of the small amounts of shared variants
fluctuated in these subjects from decreasing with a rate similar to
the virus in plasma to decreasing with a slow rate similar to that of
the CSF-compartmentalized variants (see Table 2).
For each CSF sample time point the CSF white blood cell
(WBC) count was measured to determine if any subjects had CSF
pleocytosis (defined as .5 cells/ml; [48,49]). We found that all four
subjects with rapid CSF-compartmentalized variant decay either
had high CSF WBC levels at entry (4033=28 cells/ml; 5003=46
cells/ml; 7036=240 cells/ml; 4051=12 cells/ml), or the CSF WBC
levels increased while on therapy. Conversely, the four subjects
with neurological disease that displayed slower CSF-compartmen-
talized variant decay either had extremely low levels of CSF WBCs
at entry (4013=10 cells/ml; 5002=66 cells/ml; 4059=1 cells/ml;
7115=12 cells/ml), or the CSF WBC levels decreased to low levels
after the initiation of antiretroviral therapy. We examined the CSF
WBC levels of these two groups in more detail by calculating the
CSF WBC average for each subject from baseline through the first
14 days of antiretroviral therapy. The subjects with rapid CSF-
compartmentalized variant decay had higher CSF WBC averages,
while subjects with slower or biphasic CSF-compartmentalized
variant decay had lower CSF WBC averages (see Table 1), and
this difference was statistically significant (p=0.029 using a two-
tailed Mann-Whitney test). It has been reported that HIV-1-
infected subjects with CD4 counts below 50 cells/ml have reduced
CSF pleocytosis [49]. We also examined whether the viral decay
rates measured by HTA were correlated with the degree of
immunodeficiency by analyzing CD4 counts for each group of
subjects. The four subjects with rapid CSF-compartmentalized
variant decay had significantly higher baseline CD4 counts (see
Table 1) compared to the four subjects with slower CSF-
compartmentalized variant decay (p=0.006 using a two-tailed
unpaired t-test). Thus, in subjects with HIV-1–associated neuro-
logical disease, viral decay rates are associated with the degree of
immunodeficiency and CSF pleocytosis.
We did not detect an association between CSF pleocytosis and
rapid viral decay in the CSF for asymptomatic subjects. The CSF
WBC average was calculated for each subject as stated above, and
Table 2. HIV-1 variant decay.
Subject ID
% HIV-1 RNA decrease
(days on HAART)
Plasma Half-life
(days)
CSF-Compartmentalized
Variant Data CSF Shared Variant Data % Diff.c
Plasma CSF % CSF VL
a Half-life (days)
b % CSF VL
a Half-life (days)
b
4012 96 (10) 97 (10) 1.36 0 N/A 100 1.73 29
4014 92 (7) 95 (7) 1.96 83.6 1.9 16.4 1.3 37
4021 90 (5) 82 (5) 1.2 7 .1.59
f 93 1.59 36
4022 87 (4) 93 (4) 1.01 37 0.75 63 0.79 47
4023 90 (3) 79 (3) 0.58 0 N/A 100 0.88 58
4030 90 (3) 90 (3) 1.81 0 N/A 100 1.83 10
5005 97 (10) 98 (10) 2.27 100 2.04 0 N/A 78
4033 92 (8) 92 (8) 1.64 77 1.44 23 2.44 72
4051 95 (10) 94 (10) 2.32 39 2.74 61 2.19 36
5003 54 (6) 82 (6) 2.69
e 94 1.23 6 1.05 88
7036 99 (25) 99 (25) 2.91 82 3.67 18 2.95 80
4013 93 (15) 20 (9) 2.32 73 28.5 27 4.3 78
76 (15) 3.9 2.0
4059 98 (14) 62 (14) 2.35 92 9.85 8 5.84 46
5002 98 (6) Inc. (6)
d 1.42 98 No decay 2 No decay 72
93 (28) 4.24 1.76
7115 99 (10) 40 (10) 1.25 47 No decay 53 4.88 65
95 (33) 6.4 6.05
aBased on the region of env (V1/V2 or V4/V5) that was the most reproducible by two independent HTA replicates.
bReported half-lives are the average calculated from decay analyses of two independent HTA replicates. N/A=not applicable.
cPercent difference values between plasma and CSF viral populations as measured by HTA. Reported values are the average calculated from two independent HTA
replicates (see refs. [39,41] for methods).
dTotal CSF viral load increased initially for subject 5002.
eTotal plasma viral decay for subject 5003 was calculated for the drop in viral load from days 3 to 6 on HAART. There was a slight increase in plasma viral load from days
6 to 10 on HAART, which can be seen in Figure 2B, but this increase does not seem to be significant. Although the baseline samples were not available for analysis, we
know that the baseline plasma viral load was 126,000 copies/ml, and this subject had undetectable viral loads in both plasma and CSF by 2 months post-HAART, so
there was an overall good response to antiretroviral therapy. The small variation in plasma viral load from days 6 to 10 on therapy could be explained by a number of
technical, pharmacological, and/or biological factors.
fA compartmentalized variant was detected for subject 4021 in the day 5 CSF sample; however, the relative abundance of this variant was less than other bands
detected that were not reproducible by HTA, indicating that the detection of this band may be due to inefficient sampling and low viral load. It is equally possible that
this band represents a reproducible compartmentalized variant that is decaying more slowly than the other variants detected by HTA. Therefore, the half-life for the
CSF-compartmentalized variants is listed as .1.59 days (a half-life of 1.59 days was measured for CSF shared variants).
doi:10.1371/journal.ppat.1000395.t002
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PLoS Pathogens | www.plospathogens.org 4 April 2009 | Volume 5 | Issue 4 | e1000395Figure 1. Longitudinal HTA analysis and HIV-1 decay in the blood plasma and CSF of asymptomatic subjects. (A) Longitudinal V1/V2 or
V4/V5 HTA analysis of HIV-1 using paired blood plasma and CSF samples from 7 asymptomatic subjects that were initiating antiretroviral therapy. The
HTA shown for subject 4014 targeted the V1/V2 region of env, and the V4/V5 HTA is shown for all other subjects. Sample time points are listed above
each HTA gel as days on HAART (DOH) with day 0 indicating the day that antiretroviral therapy was started. CSF-compartmentalized variants are
indicated with a filled black circle next to the gel image. The V4/V5 HTA analysis for subject 4021 revealed a compartmentalized variant in the day 5
CSF sample, not present in the blood plasma, that was reproducible by HTA; however, the relative abundance of this variant (3.6%) was less than that
of other bands detected in the same sample that were not reproducible by HTA, indicating that the detection of this band may be due to inefficient
sampling and low viral load. Compartmentalized variants were not detected for three subjects. (B) HIV-1 decay kinetics in the blood plasma and CSF.
Viral variants in the CSF were categorized as either compartmentalized or shared between the plasma and CSF for the decay analysis. Total plasma
viral load decay is shown in red, CSF-compartmentalized variant decay is denoted by the solid blue line, and decay of variants shared between the
plasma and CSF is shown by the dashed blue line. It should be noted that in our decay analysis for subject 4012 we assumed the viral load at day 0
would be similar to the viral load measured for the baseline samples at day 29.
doi:10.1371/journal.ppat.1000395.g001
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PLoS Pathogens | www.plospathogens.org 5 April 2009 | Volume 5 | Issue 4 | e1000395Figure 2. Longitudinal HTA analysis and HIV-1 decay in blood plasma and CSF of neurologically symptomatic subjects. (A)
Longitudinal V4/V5 HTA analysis of HIV-1 in paired blood plasma and CSF samples from 1 subject with MCMD (subject 4013) and 7 subjects with HIV-
associated dementia that were initiating HAART. Plasma (P) and CSF sample time points are listed above each HTA gel as days on HAART (DOH), and
day 0 indicates the start of antiretroviral therapy. CSF-compartmentalized variants are indicated by a filled black circle. (B, C) HIV-1 decay kinetics in
the blood plasma and CSF viral populations. Viral variants in the CSF were categorized as either compartmentalized in the CSF or shared between the
plasma and CSF. Total plasma viral load decay is shown in red, CSF-compartmentalized variant decay is denoted by the solid blue line, and decay of
variants shared between the plasma and CSF is shown by the dashed blue line. Four subjects (4033, 5003, 7036, 4051) displayed rapid decay in their
CSF-compartmentalized variant population (shown in panel B), while the other four subjects (4013, 5002, 4059, 7115) had slower decay of CSF-
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variants detected in the CSF of asymptomatic subjects decayed
rapidly upon the initiation of antiretroviral therapy; however, we
found that the presence of CSF-compartmentalized variants was
associated with higher average CSF WBC levels. All four of the
asymptomatic subjects that did not have compartmentalized virus
had low average CSF WBC counts (4012, 4030, 4023, 4021),
while the three asymptomatic subjects that had detectable CSF-
compartmentalized variants also had higher average CSF WBC
levels (5005, 4022, 4014; see Table 1). Thus in the asymptomatic
subjects the presence of pleocytosis may be associated with an
early inflammatory response to increased levels of autonomously
replicating virus.
Slower decay in neurologically symptomatic subjects is
not associated with CNS drug penetration, drug
resistance mutations, or V3/X4 sequence differences
Some antiretroviral drugs have poor penetration into the CNS
[50]. In order to determine whether the differential decay we
detected by HTA was associated with poor CNS drug penetration,
we calculated the CNS Penetration Effectiveness (CPE) rank [50]
for the drug regimens that each of the 15 subjects were receiving at
the time of sample collection (see Table 1). Drugs that have poor
penetration into the CNS were assigned a rank of 0, intermediate
penetration was assigned a rank of 0.5, and high penetration was
assigned a rank of 1 [50]. The four subjects that showed a longer
viral half-life by HTA analysis had CPE ranks ranging from 2.0 to
2.5, while the other subjects that displayed rapid viral decay had
CPE ranks from 1.5 (5 subjects) to 3.5 (1 subject). All subjects with
neurological disease had CPE ranks above 2.0 except for subject
5003 (CPE rank=1.5). A previous study reported that CPE ranks
below 2.0 were associated with a significant (88%) increase in the
ability to detect virus in the CSF, and higher CSF viral loads were
associated with low CPE ranks [50]. All of the subjects with longer
viral half-lives had CPE ranks of 2.0 or above, suggesting that the
slower HIV-1 decay we detected by HTA was not associated with
poor CNS drug penetration. Alternatively, there could be infected
cells located in parenchymal compartments that are less accessible
to drugs, but this seems unlikely because the virus still has access to
the CSF.
We also investigated the possibility that slower decay was a
result of drug resistance mutations present in the viral population
in the CSF. Drug resistance mutations were measured for CSF
samples of subjects 4013, 5002, 4059, and 7115. The resistance
test was conducted for time points after the initiation of drug
selection to allow for enrichment of any potential drug resistant
variants. Subjects 4013, 5002, and 4059 showed no evidence of
resistance mutations in reverse transcriptase (RT) or protease that
confers resistance to antiretroviral drugs (data not shown). Subject
7115 had the resistance mutation K103N in RT, which confers
resistance to non-nucleoside RT inhibitors (NNRTI). However, at
the time of this study, subject 7115 was not taking an NNRTI, and
was instead on a drug regimen that included zidovudine,
lamivudine, and lopinavir. Therefore, there is no evidence that
drug resistance played a role in the slower viral decay detected by
HTA in these four subjects.
Using the biotin-V3 HTA procedure, we also examined
whether slower viral decay was associated with V3 sequence
differences. The biotin-HTA is a modification of the original HTA
method that incorporates a biotin tag into the probe to allow direct
Figure 3. Summary of HIV-1 half-lives from asymptomatic and
neurologically symptomatic subjects. Half-lives were calculated for
total plasma viral load decay (Plasma), total CSF viral load decay (CSF),
and CSF-compartmentalized variant decay (CSF compartmentalized
variants). The half-lives were calculated using the time points when the
variant load initially dropped after each subject initiated antiretroviral
therapy. All half-lives listed in the figure are the average calculated from
decay analyses of two independent HTA replicates. Half-lives are listed
for the seven new asymptomatic subjects analyzed in this study plus
four asymptomatic subjects (labeled as 4 Asy.) that were previously
reported [24], 1 subject with MCMD (subject 4013), and 7 subjects with
HIV-1–associated dementia. The asymptomatic subjects include: 4012
(open green square), 4030 (open yellow-green diamond), 5005 (brown
square), 4023 (green plus symbol), 4022 (open, inverted blue triangle),
4014 (orange rectangle), 4021 (open fuchsia triangle), and 4 Asy. (gray
circles). The subjects with HIV-associated neurological disease include:
4033 (purple triangle), 5003 (inverted green triangle), 7036 (teal circle),
4051 (open purple circle), 4013 (blue square), 5002 (red diamond), 4059
(black6symbol), and 7115 (black irregular circle). Two different half-lives
are listed for subjects 4013, 5002, and 7115 for both total CSF viral
decay (CSF) and CSF-compartmentalized variant decay (CSF-compart-
mentalized variants). Each of these three subjects showed biphasic
decay by HTA analysis, and the half-life data point denoted with the
asterisk represents the phase 1 half-life (slower), while the half-life
lacking the asterisk was calculated for phase 2 of decay (faster). The
CSF-compartmentalized variant population increased initially for
subjects 5002 and 7115, so there was no decay detected for these
subjects during phase 1 and their half-lives are listed on the graph as
.30 days. Similarly, the total CSF viral load increased for subject 5002
during phase 1 of decay and the half-life is listed on the graph as .30
days.
doi:10.1371/journal.ppat.1000395.g003
compartmentalized variants (shown in panel C). Subjects 4013, 5002, and 7115 showed differential decay of CSF-compartmentalized variants where
initially the compartmentalized variant population decreased very slowly (4013) or increased (5002, 7115) after the start of therapy, and at
subsequent time points began decreasing at a faster rate (panel C). In our decay analysis for subjects 4051 and 7115 we assumed that the viral load at
day 0 would be similar to the viral load measured for the baseline samples at day 29 for subject 4051 and at day 225 for subject 7115. In this regard,
subject 7115 was followed longitudinally for several years prior to the start of antiretroviral therapy, and the viral loads in both the plasma and CSF
samples remained relatively constant over time (data not shown).
doi:10.1371/journal.ppat.1000395.g002
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newly developed HTA procedure resolves minor variants in the
gel, and then allows the recovery and sequence analysis of both
major and minor HIV-1 V3 variants from complex viral
populations [51]. Following V3 PCR amplification and HTA
analysis, we excised the gel fragments containing the V3
heteroduplexes, purified the query DNA strand using streptavi-
din-coated magnetic DynabeadsH, and directly sequenced the
subsequent V3 PCR products [51]. The migration patterns for the
V3 heteroduplexes and the inferred V3 amino acid sequence
obtained for the heteroduplex in each gel band are shown in
Figure 4. The biotin-V3 HTA procedure was conducted on
Figure 4. Examination of the V3 region of env using the biotin-V3 HTA. (A) Biotin-V3 HTA analysis of the baseline samples collected for
asymptomatic and neurologically symptomatic subjects. Plasma samples (P) were analyzed for all subjects, and CSF samples (C) were analyzed for
HAD subjects. The asterisk indicates the double-stranded probe band, and shifted heteroduplex bands are noted with arrowheads and numbers. (B)
Summary table of the V3 sequence information obtained using the biotin-V3 HTA procedure. The desired V3 bands were excised from the dried gel,
the query strand DNA was purified and PCR amplified, and the V3 PCR products from each band were sequenced. The sample type (P/C; P=plasma
sample, C=CSF sample), relative abundance (Rel. Ab.), and PSSM score (0=R5-like sequence, 1=X4-like sequence, N/A=not applicable) for each
sequence are listed in the table. Note: the V3 PCR primers used to amplify the V3 products extend into the first four and the last three amino acids of
the V3 sequence. The V3 sequences provided do not include these amino acids; however, we added the JRFL consensus amino acid sequence to the
beginning (CTRP) and end (AHC) of each V3 sequence to predict coreceptor usage using PSSM. Mixtures in the sequence peaks were detected at
specific positions in V3 bands from subject 4051 plasma and CSF samples, and these mixtures are noted in the reported amino acid sequences.
doi:10.1371/journal.ppat.1000395.g004
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and CSF samples were analyzed for subjects with HIV-associated
dementia. No significant V3 sequence differences were detected
between asymptomatic and symptomatic subjects, or between
subjects with rapid versus slow decay by HTA (Figure 4B). Only
one subject (4014) had V3 sequences that were X4-like by the
Position-Specific Scoring Matrix (PSSM) method [52] of predict-
ing co-receptor usage based on genotype. We did note that two
subjects with slower decay by HTA had compartmentalized V3
variants detected in the CSF viral population that were much
more R5-like by sequence compared to the V3 sequence variants
detected in the plasma viral population. However, R5-like V3
sequences were also detected in the CSF for HAD subjects with
rapid viral decay, indicating that V3 sequence differences and co-
receptor usage are not responsible for the differential decay
detected by HTA.
Discussion
There are several lines of evidence that support the idea that
HIV-1 can replicate in the central nervous system (CNS). HIV-1-
infected macrophages and microglia have been detected in the
brains of subjects with HIV-1–associated dementia (HAD) at
autopsy [6,53,54]. In addition, genetically distinct HIV-1 variants,
different from those in the peripheral blood, are seen in the CNS
of subjects with HAD [7,12–15]. These inferences can be extended
using CSF as a surrogate for the CNS where genetic compart-
mentalization can be detected when comparing blood and CSF
viral variants [20–23], and bulk virus in the CSF of subjects
initiating HAART can decay with different kinetics compared to
virus in the blood [16,19,55]. Furthermore, it appears that this
independent replication is relevant, if not causal, of HIV-
associated neuropathogenesis. The extent of compartmentaliza-
tion in the CSF, as measured by the heteroduplex tracking assay,
increases in subjects with HAD, suggesting more sustained
autonomous replication is associated with the neurological disease
state [21,22]. Also, slow decay of virus in the CSF compared to the
blood is associated with subjects with neurological disease,
especially HAD subjects, suggestive of virus being produced from
a different cellular source [16,19,55]. In addition to viral genetic
compartmentalization there are other markers of neuropathogen-
esis in HIV-1-infected individuals, such as CSF neopterin [56,57],
CSF light-chain neurofilament protein [57–59], and CSF
chemokine levels [60–64]. In the current work we have attempted
to combine the observations of viral genetic compartmentalization
and differential decay in subjects initiating HAART by comparing
the rates of decay of variants shared between the CSF and the
blood versus those variants that were compartmentalized in the
CSF. The goal of this work was to examine the link between
compartmentalized virus as a marker for autonomous replication
in the CNS and the production of virus in the CNS by long-lived
cells.
We used heteroduplex tracking assays (HTAs) targeting the
variable regions of env to identify CSF-compartmentalized variants
and variants shared between the CSF and blood plasma, and then
measured the viral decay kinetics of these two distinct classes of
viral variants after the initiation of antiretroviral therapy for
asymptomatic and neurologically symptomatic subjects. We found
that plasma HIV-1 variants decayed rapidly for both neurolog-
ically asymptomatic and symptomatic subjects, indicating that
short-lived cells, presumably activated CD4
+ T cells, are the
predominant source of virus in the periphery during all disease
stages. Additionally, shared and compartmentalized variants in the
CSF of seven asymptomatic subjects decayed rapidly, with a mean
half-life of 1.35 and 1.57 days, respectively. These decay rates are
consistent with our previous study of four asymptomatic subjects
[24]. HIV-1 viral load decays in the peripheral blood with the
same half-life as a productively infected CD4
+ T cell (approxi-
mately 2 days; [25,27,28]), so it is most likely that CSF-shared and
compartmentalized virus in asymptomatic subjects is originating
from a short-lived cell type, such as a CD4
+ T cell. The level of
HIV-1 compartmentalization in the CSF in these asymptomatic
subjects varied, and we noted that there was a trend of increased
CSF pleocytosis in the asymptomatic subjects with greater
compartmentalization.
We also examined HIV-1 decay in subjects with neurological
disease that were starting HAART. Rapid viral decay was
measured for CSF-compartmentalized variants after the initiation
of HAART for four HAD subjects (t1/2 mean=2.27 days), while
slow viral decay was measured for CSF-compartmentalized
variants from the other four subjects with neurological disease
(t1/2 range=9.85 days to no initial decay). It is known that HIV-1
may persist in the CNS during antiretroviral therapy due to
insufficient CNS penetration of some antiretroviral drugs [2,9–11].
We determined that the slow decay detected for CSF-compart-
mentalized variants was not associated with poor CNS drug
penetration, the presence of drug resistant virus in the CSF, or the
detection of X4-like virus genotypes. It has been suggested that
HIV-1 produced by long-lived cell lineages such as macrophages,
microglia, and resting CD4
+ T cells most likely decays with a half-
life of 14 days or greater [27–29]. The longer half-lives we
detected suggest that compartmentalized HIV-1 in the CSF of
some neurologically symptomatic subjects may be originating from
a long-lived cell type.
While slower HIV-1 decay was detected for half of the subjects
with neurological disease, compartmentalized variants in the CSF
of some subjects decayed rapidly. Further analysis revealed that
the differential decay measured for CSF-compartmentalized
variants in subjects with neurological disease was correlated with
the degree of CSF pleocytosis. Four of the eight subjects with HIV-
associated neurological disease displayed rapid CSF-compartmen-
talized variant decay, and this was correlated with higher CSF
WBC levels (moderate to severe pleocytosis). The compartmen-
talized variants detected in the CSF of the four other subjects
showed slow or biphasic decay after the initiation of HAART, and
this was associated with lower CSF WBC levels (no or mild
pleocytosis). Additionally, the subjects with rapid CSF-compart-
mentalized variant decay had significantly higher CD4 counts
than subjects with slow compartmentalized variant decay,
indicating that subjects with slow decay of CSF-compartmental-
ized virus have increased immunodeficiency. We suggest that
more profound immunodeficiency results in fewer lymphocytes
trafficking into the CNS, which is consistent with the decreased
CSF WBC counts for the subjects with slow decay. HIV-1
infection can be associated with CSF pleocytosis in neurologically
symptomatic subjects, asymptomatic subjects, and individuals
lacking any CNS opportunistic infections [48]. Additionally, some
studies have shown that CSF WBC levels are correlated with CSF
HIV-1 RNA concentrations [49,65,66], and CSF pleocytosis has
been shown to decrease after the initiation of antiretroviral therapy
[48]. In this current study we found an association between the
extent of immunodeficiency, CSF pleocytosis and rapid HIV-1
decay kinetics for compartmentalized variants in the CSF of
neurologically symptomatic subjects, although the strength of the
interpretation is somewhat limited by our small sample size.
Taken together, we have developed a model of HIV-1 infection
in the CNS in the context of neurological disease (Figure 5). The
model has several features that incorporate viral genetic
Origin of Compartmentalized HIV-1
PLoS Pathogens | www.plospathogens.org 9 April 2009 | Volume 5 | Issue 4 | e1000395compartmentalization, CSF pleocytosis, and viral decay rates in
the CSF as a measure of the virus-producing cell. First, the
majority of the virus detected in the CSF of a subset of
asymptomatic subjects is imported from the peripheral blood
(Figure 5A). HIV-1-infected CD4
+ T cells in the peripheral blood
release virus that is detectable in the blood plasma and the CSF
and that decays rapidly upon the start of antiretroviral therapy,
representing the relatively fast turnover of uninfected CD4
+ T
cells. HIV-1-infected CD4
+ T cells in the peripheral blood can
migrate from the periphery into the CNS and secrete virus in the
CNS that is genetically similar to virus in the peripheral blood. No
or only mild pleocytosis was detected for this group of
asymptomatic subjects, and we suggest this represents minimal
inflammation in the CNS. It is possible that some CNS HIV-1
variants are independently replicating at a low level in these
asymptomatic subjects, but we were not able to detect these
genetic variants above the background of virus recently imported
from the periphery. In these subjects virus decays with the half life
of peripheral T cells, the presumed source of the virus.
A second pattern exists for the other asymptomatic subjects and
also for a subset of the neurologically symptomatic subjects. There
is increased compartmentalization of HIV-1 in this subset of
asymptomatic subjects, and the majority of virus detected in the
CSF is compartmentalized in HIV-1-infected individuals with
severe neurological disease. In addition, both of these groups have
increased pleocytosis. We found that CSF-compartmentalized
variants decayed rapidly upon the initiation of antiretroviral
therapy in these remaining asymptomatic subjects and in this
subset of four subjects with HIV-1–associated dementia. It is
possible that compartmentalized variants detected in these subjects
are produced by long-lived cells in the CNS; however the majority
of the compartmentalized virus is produced by a short-lived cell
type. We propose that compartmentalized virus may be main-
tained by long-lived cells in the CNS and that this virus is
amplified by short-lived trafficking CD4
+ T cells to detectable
Figure 5. Model of HIV-1 infection in the central nervous
system. CD4
+ T cells are represented by open circles, macrophages are
represented by the irregularly shaped cells, monocytes are represented
by open circles labeled with an M, blood plasma viral variants are
represented by the red virus particles, and CNS compartmentalized viral
variants are represented by the blue virus particles. (A) HIV-1 infection
in the CNS of a subset of asymptomatic subjects without detectable
compartmentalized virus or CSF pleocytosis. All HIV-1 detected in the
CSF decays rapidly after the initiation of therapy, suggesting that CSF
virus is coming from a short-lived cell type. (B) HIV-1 infection in the
CNS of asymptomatic and neurologically symptomatic subjects with
compartmentalization, high CSF pleocytosis and rapid viral decay. In
this model, local CNS virus is able to replicate to higher titers during
periods of immunodeficiency and stimulate an inflammatory response
in the CNS. Uninfected CD4
+ T cells that migrate into the CNS can
become infected by compartmentalized HIV-1 produced by macro-
phages and microglia in the CNS, and then amplify the local CNS-
compartmentalized virus to higher concentrations. Thus, a rapid decay
rate for compartmentalized virus is detected after the initiation of
antiretroviral therapy. (C) HIV-1 infection in the CNS of neurologically
symptomatic subjects with slow viral decay. Our data indicate that
compartmentalized variants in the CSF of HAD subjects are originating
from long-lived macrophages and microglia in the CNS, resulting in a
slow decay rate for compartmentalized virus. We propose that periods
of profound immunodeficiency allow compartmentalized virus in the
CNS to replicate to high titers, and that in the absence of other
lymphocytes (such as CD4
+ T cells) peripheral, uninfected monocytes
may migrate into the brain parenchyma in large numbers and
differentiate into perivascular macrophages. These macrophages can
then become infected by compartmentalized HIV-1 variants in the CNS
and support viral replication at detectable levels.
doi:10.1371/journal.ppat.1000395.g005
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the CSF of HAD subjects (Figure 5B). The elevated level of
pleocytosis is indicative of an inflammatory response, most likely to
the autonomously replicating virus. Increased levels of CSF white
blood cells may account for the influx of T cells that could be the
source of the short-lived cells that are amplifying the compart-
mentalized virus. We would expect that most of the infiltrating T
cells are HIV-specific, although some lymphocytes may be
migrating into the CNS due to a general inflammatory
environment. The asymptomatic subjects in this group have the
hallmarks of viral pathogenesis associated with neurological
disease and may be at risk for transition to HAD.
Third, we detected slow decay of compartmentalized variants in
the CSF for the four remaining subjects with neurological disease.
These subjects shared the feature of viral genetic compartmental-
ization but did not show high levels of pleocytosis. Additionally,
this subject group had the lowest blood CD4
+ T cell counts
(Table 1), indicating a state of increased immunodeficiency. We
suggest that these subjects have more profound immunodeficiency,
which would allow even more extensive viral replication and
compartmentalization in the CNS (Figure 5C). Increased immu-
nodeficiency would result in reduced trafficking of CD4
+ T cells
into the CNS, so these cells would no longer be present to amplify
virus from local CNS tissue, consistent with the reduced
pleocytosis in this group. The slow decay rate of virus in the
CSF in the absence of inflammatory cells suggests that
compartmentalized HIV-1 in the CNS of these HAD subjects is
originating from a long-lived cell type, such as perivascular
macrophages and/or microglia in the CNS. Virus is unlikely to be
coming from T cells that are persisting in the absence of immune-
mediated killing since there is still rapid viral decay in the
peripheral blood. The CSF viral loads of all four subjects
displaying slow decay were high, similar to subjects with rapid
viral decay, suggesting that a large amount of compartmentalized
virus is being produced by longer-lived cells in the CNS. This may
suggest that peripheral, uninfected monocytes may migrate into
the brain parenchyma and differentiate into perivascular macro-
phages to levels that can sustain high viral loads in the CSF. An
influx of monocytes into the CNS could also allow the entrance of
peripherally-infected monocytes, which would explain the slower
decay we detected for shared variants in the CSF of these subjects.
Our studies support a model where increasing levels of
autonomous viral replication in the CNS first induces an
inflammatory state that then progresses to neurologic disease with
increasing immunodeficiency. More profound immunodeficiency
ultimately reveals long-lived cells that are able to maintain
independent replication of virus in the CNS. Several env gene
markers have been described in viral sequences taken at autopsy
and linked to the ability of HIV-1 to infect macrophages [12,13].
The CSF provides an alternative window on these viral sequences
where the evolution of the virus and its properties can be followed
over time and into the disease state. Viral genetic compartmen-
talization and other markers of CNS inflammation could also play
an important role in defining subjects at risk of progression to
neuropathogenesis in the absence of therapeutic intervention.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of California at San
Francisco. All subjects provided written informed consent for the
collection of samples and subsequent analysis.
Subject population and sampling
The samples from study subjects used for variant decay analysis
were collected during previous studies carried out at the University
of California at San Francisco. All subjects used in this study were
HIV-1-infected subjects that were initiating highly-active antiret-
roviral therapy. Subjects 4012, 4013, 4014, 5002, 5003, and 5005
were recruited from a study examining antiretroviral therapy
responses in the CSF, and are described in more detail in ref. [67].
Serial blood plasma and cerebrospinal fluid (CSF) samples were
collected at baseline prior to the start of therapy and at varying
intervals thereafter. Plasma and CSF HIV-1 RNA concentrations
were determined using the Amplicor HIV Monitor kit (Roche).
CSF white blood cell counts were measured by routine methods in
the San Francisco General Clinical Laboratory. Drug resistance
mutations were analyzed for CSF samples of subjects 4013, 5002,
4059, and 7115 using the TRUGENEH HIV-1 Genotyping Test
Resistance Report using GuideLines
TM Rules 12.0 (Bayer
HealthCare).
RNA isolation, RT–PCR, and HTA
Viral RNA isolation, RT–PCR, and HTA procedures were
conducted as previously described [24,39–41]. Briefly, viral RNA
was isolated from blood plasma and CSF samples (140 ml) using
the QIAmp Viral RNA kit (Qiagen). Prior to RNA isolation, all
CSF samples were centrifuged at 2,500 rpm for 5 minutes to
remove any contaminating cellular debris. Samples with viral
RNA levels less than 10,000 copies/ml were pelleted (0.5–1.0 ml)
by centrifugation at 25,0006g for 1.5 hours prior to RNA
isolation to increase template number and improve sampling.
Reverse transcription and PCR amplification of the V1/V2, V3,
and V4/V5 regions of env were conducted with 5 ml of purified
RNA (from 60 ml column elution volume) using primers that have
been previously described for V1/V2 [39,41], V3 [51]; and V4/
V5 [41] and using the Qiagen One-Step RT-PCR kit (Qiagen) as
per manufacturer’s instructions.
Heteroduplex annealing reactions were conducted as previously
described [39,40]. The heteroduplexes were separated by 6%
native polyacrylamide gel electrophoresis for V1/V2 and V4/V5
HTA [24,39], and by 12% PAGE for biotin-V3 HTA [51]. The
HTA probes used in these studies have been previously reported:
V1/V2 Ba-L probe [39,41], V1/V2 JRFL probe [39,41], V4/V5
NL4-3 probe [24], V4/V5 YU2 probe [41], and the V3 Mut-1
probe [51]. The HTA gels were dried under vacuum, and bands
were visualized by autoradiography. For the biotin-V3 HTA
procedure, the desired labeled bands were excised from the dried
gels, the DNA was purified from the gel, and the V3 sequence was
obtained as previously described [51]. Duplicate RT-PCR
products were analyzed by HTA for each sample to validate
sampling and ensure reproducibility of the HTA pattern at each
time point. Any time points where the HTA pattern between the
two replicates differed significantly (.20%) were not used in the
data analysis. Percent difference values between plasma and CSF
viral populations were calculated as previously described [39,41].
Phosphorimager analysis and half-life calculations
The dried HTA gels were exposed to a PhosphorImager screen,
and the relative abundance of each detected viral variant
(heteroduplex) was calculated using ImageQuant software (Mo-
lecular Dynamics). The variant RNA concentration was calculated
by multiplying the relative abundance of each individual variant
by the total HIV-1 RNA concentration for that sample. Variants
in the CSF were considered compartmentalized by HTA if they
were either unique to the CSF or if they had a substantially higher
copy number in the CSF compared to the plasma. Compartmen-
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when the viral load initially dropped after the start of antiretroviral
therapy.
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